BNT323-01: A phase 3 trial of trastuzumab pamirtecan (HER2 ADC) versus investigator’s choice of chemotherapy in pretreated patients with HER2-expressing recurrent endometrial cancer (EC)

International Journal of Gynecological Cancer 2026

View at publisher
Authors: Hanna Mellin Dahlstrand, Jae-Hoon Kim, Peng‐Hui Wang, Kathleen N. Moore, David Cibula, Bhavana Pothuri, Sandro Pignata, Keri-Lee Geneser, Fernanda Musa, Maria Jesus Rubio Pérez, Xiaohua Wu, Elena Ioana Braicu
+8 more Fatih Köse, Joannie Neveu, Philip R. Debruyne, Laura Mansi, Ji Hyun Lee, Zifang Guo, John McGrane, Floor Jenniskens Backes
DOI: 10.1016/j.ijgc.2025.103204
Cited by: 0

Fields of Study & Subjects

Endometrial and Cervical Cancer Treatments HER2/EGFR in Cancer Research Gastric Cancer Management and Outcomes

Publication details

Journal / source
International Journal of Gynecological Cancer
Volume
36
Issue
2
Pages
103204–103204
Publication date
1 February 2026
Language
EN